231PD - A phase II study of the cell cycle checkpoint kinases 1 and 2 (CHK1/2) inhibitor (LY2606368; prexasertib) in sporadic triple negative breast cancer...

Date 09 October 2016
Event ESMO 2016 Congress
Session Breast cancer, metastatic
Topics Breast Cancer
Presenter Fatima Karzai
Citation Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365
Authors F. Karzai1, A. Zimmer2, S. Lipkowitz2, C.M. Annunziata2, B. Parker2, N. Houston2, I. Ekwede2, E.C. Kohn2, J. Lee2
  • 1National Institute On Miniority Health And Health Disparities, National Institutes of Health, 20892 - Bethesda/US
  • 2Women's Malignancies Branch, National Cancer Institute, 20892 - Rockville/US



CHK1/2 are major cell cycle regulators in tumors with p53 dysfunction, such as TNBC. Second-generation CHK1/2 inhibitor, prexasertib monomesylate monohydrate, showed preliminary single agent activity in advanced cancer pts. We hypothesize that prexasertib may yield clinical benefit in sporadic TNBC pts.


Eligible pts have recurrent TNBC with no deleterious germline BRCA mutation or no family history of hereditary breast and ovarian cancer syndrome; good end organ function and safely biopsiable disease. Prexasertib was administered at 105 mg/m2 IV once every 14 days on a 28-day cycle. Response was assessed every 2 cycles by RECISTv1.1 and safety by CTCAEv4 per cycle. Primary endpoint is overall response rate (ORR). Optimal two- stage design was used; if ≥1 response is seen in the first 9 pts, then accrual continues to 24 pts per cohort.


9 wild type BRCA TNBC pts have been treated in the first stage (median age 55.3 yrs [29-72 yrs] and median ECOG PS 1 [0-1]). The median number of prior therapies was 4 (2-10). 1 PR (3 mo) was observed (ORR 11%). 4 of 9 evaluable pts attained SD > 3 mo (median 4.5 mo [3-5]). Grade 3/4 AEs include neutropenia (89%), anemia (33%) and thrombocytopenia (22%). The median duration of grade 3/4 neutropenia was 5.5 (3-19) days. Grade 3/4 neutropenia resolved to less than grade 3/4 within 7 days in 5/9 pts. 1 pt required dose reduction to DL-1 (80 mg/m2) due to grade 4 neutropenia. 6 pts required GCSF support to avoid treatment delays. 3 pts received pRBC transfusion due to grade 2/3 anemia. 1 pt with grade 3 thrombocytopenia required platelet transfusion to avoid procedure-related bleeding.


Prexasertib monotherapy showed modest single agent activity in sporadic TNBC pts and continues to enroll in second stage. Tri-lineage marrow toxicity was observed. Prophylactic GCSF should be considered.

Clinical trial identification


Legal entity responsible for the study

National Cancer Institute, NIH Rockville, MD USA


This work was funded by the Intramural Program of the Center for Cancer Research, NCI, National Institutes of Health, USA.


All authors have declared no conflicts of interest.